Fairmount Funds Management LLC

In its 13F for Q1 2026 (holdings as of March 31, 2026, filed May 15, 2026), Fairmount Funds Management LLC reported 12 stock positions worth $1.4 billion. Its top holding was Damora Therapeutics (DMRA) at 16.3% of the portfolio, followed by Dianthus Therapeutics (DNTH, 15.4%) and Cogent Biosciences (COGT, 15.3%). Compared with Q4 2025, it opened 1 new position, sold out of 2, added to 2 and reduced 3. The biggest buy was a new position in Damora Therapeutics (DMRA) and the biggest sale Apogee Therapeutics (APGE, shares −85%).

Most Recent 13F
Q2 2026
Location
WEST CONSHOHOCKEN, PA
CIK
0001802528
Portfolio Value
$1.4B (Q1 2026)
SEC Filing
0001104659-26-062419 ↗ filed May 15, 2026

Holdings Value

0$500.0M$1.0B$1.5B$2.0B Q1 2024: $917.4M Q1 2024 Q2 2024: $885.1M Q2 2024 Q3 2024: $1.2B Q3 2024 Q4 2024: $1.0B Q4 2024 Q1 2025: $644.6M Q1 2025 Q2 2025: $771.9M Q2 2025 Q3 2025: $1.1B Q3 2025 Q4 2025: $1.3B Q4 2025 Q1 2026: $1.4B $1.4B Q1 2026 Q2 2026: $1.5B Q2 2026

Holdings 12 stocks · $1.4B
DMRA Damora Therapeutics Inc. 16.30% 8,713,000 $225.7M New
DNTH Dianthus Therapeutics Inc. 15.38% 2,537,191 $212.9M Add +18.7%
COGT Cogent Biosciences Inc. 15.30% 5,503,418 $211.8M Reduce -38.9%
SYRE Spyre Therapeutics Inc. 14.64% 4,018,101 $202.7M No change
ORKA Oruka Therapeutics Inc. 13.13% 3,705,262 $181.7M No change
VRDN Viridian Therapeutics Inc. 5.53% 3,914,458 $76.6M No change
ELVN Enliven Therapeutics Inc. 5.25% 1,855,644 $72.7M Reduce -50.0%
JBIO Jade Biosciences Inc. 4.62% 4,553,494 $64.0M No change
CBIO Crescent Biopharma Inc. 3.65% 2,747,866 $50.5M No change
ZBIO Zenas Biopharma Inc. 3.33% 2,359,025 $46.1M Add +6.8%
APGE Apogee Therapeutics Inc. 1.82% 298,647 $25.1M Reduce -85.4%
IKT Inhibikase Therapeutics Inc. 1.05% 8,625,000 $14.5M No change

Portfolio Sells Q4 2025 → Q1 2026
APGE Apogee Therapeutics Inc. Reduce -85.4% 1.82% −9.95
COGT Cogent Biosciences Inc. Reduce -38.9% 15.30% −9.04
NUVL Nuvalent Inc. Class A Sold out 0.00% −5.57
KNSA Kiniksa Pharmaceuticals Inte Sold out 0.00% −4.14
ELVN Enliven Therapeutics Inc. Reduce -50.0% 5.25% +0.90

Portfolio Buys Q4 2025 → Q1 2026
DMRA Damora Therapeutics Inc. New 16.30% +16.30
DNTH Dianthus Therapeutics Inc. Add +18.7% 15.38% +8.68
ZBIO Zenas Biopharma Inc. Add +6.8% 3.33% −2.77

All Filings

QuarterPositions13F Reported ValueTop Holdings
Q2 2026 12$1.5BORKA, DNTH, DMRA, COGT, JBIO
Q1 2026 12$1.4BDMRA, DNTH, COGT, SYRE, ORKA
Q4 2025 13$1.3BCOGT, APGE, SYRE, VRDN, ORKA
Q3 2025 17$1.1BDNTH, COGT, AXSM, APGE, ELVN
Q2 2025 17$771.9MAPGE, AXSM, ELVN, SRRK, SYRE
Q1 2025 15$644.6MAXSM, APGE, SYRE, ELVN, NUVL
Q4 2024 17$1.0BAXSM, NUVL, SYRE, APGE, SRRK
Q3 2024 15$1.2BAXSM, NUVL, APGE, SYRE, ELVN
Q2 2024 13$885.1MAXSM, NUVL, SYRE, APGE, ELVN
Q1 2024 15$917.4MAXSM, NUVL, APGE, DNTH, KNSA